Cargando…
MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis
Medulloblastoma (MB), the most common malignant pediatric brain tumor, is a leading cause of childhood mortality. Of the four primary subgroups, patients with group 3 tumors have the poorest prognosis. Loss of chromosome 17p is a high-risk feature associated with poor outcomes in group 3 tumors. We...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164725/ http://dx.doi.org/10.1093/neuonc/noac079.464 |
_version_ | 1784720204093194240 |
---|---|
author | Kanchan, Ranjana Perumal, Naveenkumar Khan, Parvez Doss, David Venkata, Ramakanth Chirravuri Thapa, Ishwor Vengoji, Raghupathy Kaushal, Jyoti Siddiqui, Jawed Nasser, Mohd Wasim Batra, Surinder Mahapatra, Sidhartha |
author_facet | Kanchan, Ranjana Perumal, Naveenkumar Khan, Parvez Doss, David Venkata, Ramakanth Chirravuri Thapa, Ishwor Vengoji, Raghupathy Kaushal, Jyoti Siddiqui, Jawed Nasser, Mohd Wasim Batra, Surinder Mahapatra, Sidhartha |
author_sort | Kanchan, Ranjana |
collection | PubMed |
description | Medulloblastoma (MB), the most common malignant pediatric brain tumor, is a leading cause of childhood mortality. Of the four primary subgroups, patients with group 3 tumors have the poorest prognosis. Loss of chromosome 17p is a high-risk feature associated with poor outcomes in group 3 tumors. We recently elucidated the tumor suppressive properties of a novel miR, miR-1253, on the terminal end of 17p. In further exploring its anti-neoplastic effects, we discovered that miR-1253 can disrupt iron homeostasis, causing oxidative stress and inducing lipid peroxidation. These concurrent events are capable of triggering an iron-mediated form of cell death called ferroptosis. Notably, our in silico interrogation of ferroptosis regulator genes (FRGs) in group 3 tumors revealed high expression of genes associated with iron transport and glutathione metabolism. These included mitochondrial iron transporters and GPX4, a critical regulator of ferroptosis. Restoration of miR-1253 expression in group 3 cell lines resulted in specific downregulation of ABCB7, an iron-sulfur cluster exporter, and GPX4. Consequently, cytosolic and mitochondrial labile iron pools rose, glutathione levels declined, and mitochondrial oxidative stress and lipid peroxidation were induced. These events were recapitulated by ABCB7 knockdown and potentiated cell death. Treating miR-1253-expressing cancer cells with cisplatin, a group 3 MB chemotherapeutic agent with ferroptotic properties, further elevated oxidative stress, depleted glutathione levels, and augmented lipid peroxidation, with added inhibitory effects on cell viability and colony formation. Treatment with a ferroptosis inhibitor (ferrostatin-1) lead to recovery from the cytotoxic effects of this combination therapy. Our studies highlight a novel mechanism for group 3 MB pathogenesis via ferroptosis regulation and provide a proof-of-concept for exploiting group 3 MB tumor vulnerability to iron imbalance as a novel treatment strategy. |
format | Online Article Text |
id | pubmed-9164725 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91647252022-06-05 MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis Kanchan, Ranjana Perumal, Naveenkumar Khan, Parvez Doss, David Venkata, Ramakanth Chirravuri Thapa, Ishwor Vengoji, Raghupathy Kaushal, Jyoti Siddiqui, Jawed Nasser, Mohd Wasim Batra, Surinder Mahapatra, Sidhartha Neuro Oncol Medulloblastoma Medulloblastoma (MB), the most common malignant pediatric brain tumor, is a leading cause of childhood mortality. Of the four primary subgroups, patients with group 3 tumors have the poorest prognosis. Loss of chromosome 17p is a high-risk feature associated with poor outcomes in group 3 tumors. We recently elucidated the tumor suppressive properties of a novel miR, miR-1253, on the terminal end of 17p. In further exploring its anti-neoplastic effects, we discovered that miR-1253 can disrupt iron homeostasis, causing oxidative stress and inducing lipid peroxidation. These concurrent events are capable of triggering an iron-mediated form of cell death called ferroptosis. Notably, our in silico interrogation of ferroptosis regulator genes (FRGs) in group 3 tumors revealed high expression of genes associated with iron transport and glutathione metabolism. These included mitochondrial iron transporters and GPX4, a critical regulator of ferroptosis. Restoration of miR-1253 expression in group 3 cell lines resulted in specific downregulation of ABCB7, an iron-sulfur cluster exporter, and GPX4. Consequently, cytosolic and mitochondrial labile iron pools rose, glutathione levels declined, and mitochondrial oxidative stress and lipid peroxidation were induced. These events were recapitulated by ABCB7 knockdown and potentiated cell death. Treating miR-1253-expressing cancer cells with cisplatin, a group 3 MB chemotherapeutic agent with ferroptotic properties, further elevated oxidative stress, depleted glutathione levels, and augmented lipid peroxidation, with added inhibitory effects on cell viability and colony formation. Treatment with a ferroptosis inhibitor (ferrostatin-1) lead to recovery from the cytotoxic effects of this combination therapy. Our studies highlight a novel mechanism for group 3 MB pathogenesis via ferroptosis regulation and provide a proof-of-concept for exploiting group 3 MB tumor vulnerability to iron imbalance as a novel treatment strategy. Oxford University Press 2022-06-03 /pmc/articles/PMC9164725/ http://dx.doi.org/10.1093/neuonc/noac079.464 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Medulloblastoma Kanchan, Ranjana Perumal, Naveenkumar Khan, Parvez Doss, David Venkata, Ramakanth Chirravuri Thapa, Ishwor Vengoji, Raghupathy Kaushal, Jyoti Siddiqui, Jawed Nasser, Mohd Wasim Batra, Surinder Mahapatra, Sidhartha MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis |
title | MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis |
title_full | MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis |
title_fullStr | MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis |
title_full_unstemmed | MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis |
title_short | MEDB-90. Iron Imbalance Can Potentiate Cisplatin Response in Pediatric Medulloblastoma by Regulating Ferroptosis |
title_sort | medb-90. iron imbalance can potentiate cisplatin response in pediatric medulloblastoma by regulating ferroptosis |
topic | Medulloblastoma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164725/ http://dx.doi.org/10.1093/neuonc/noac079.464 |
work_keys_str_mv | AT kanchanranjana medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT perumalnaveenkumar medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT khanparvez medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT dossdavid medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT venkataramakanthchirravuri medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT thapaishwor medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT vengojiraghupathy medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT kaushaljyoti medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT siddiquijawed medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT nassermohdwasim medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT batrasurinder medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis AT mahapatrasidhartha medb90ironimbalancecanpotentiatecisplatinresponseinpediatricmedulloblastomabyregulatingferroptosis |